Loss of betaglycan expression in ovarian cancer: role in motility and invasion.

The transforming growth factor-beta (TGF-beta) superfamily members, TGF-beta, activin, and inhibin, all have prominent roles in regulating normal ovarian function. Betaglycan, or the type III TGF-beta receptor, is a coreceptor that regulates TGF-beta, activin, and inhibin signaling. Here, we show that betaglycan expression is frequently decreased or lost in epithelial derived ovarian cancer at both the mRNA and protein level, with the degree of loss correlating with tumor grade. Treatment of ovarian cancer cell lines with the methyltransferase inhibitor 5-aza-2-deoxycytidine and the histone deacetylase inhibitor trichostatin A resulted in significant synergistic induction of betaglycan message levels and increased betaglycan protein expression, indicating that epigenetic silencing may play a role in the loss of betaglycan expression observed in ovarian cancer. Although restoring betaglycan expression in Ovca429 ovarian cancer cells is not sufficient to restore TGF-beta-mediated inhibition of proliferation, betaglycan significantly inhibits ovarian cancer cell motility and invasiveness. Furthermore, betaglycan specifically enhances the antimigratory effects of inhibin and the ability of inhibin to repress matrix metalloproteinase levels in these cells. These results show, for the first time, epigenetic regulation of betaglycan expression in ovarian cancer, and a novel role for betaglycan in regulating ovarian cancer motility and invasiveness.

[1]  R. Delorme,et al.  Mutation analysis of the NSD1 gene in patients with autism spectrum disorders and macrocephaly , 2007, BMC Medical Genetics.

[2]  G. Blobe,et al.  The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. , 2007, Cancer research.

[3]  B. Moeller,et al.  The type III TGF-β receptor suppresses breast cancer progression , 2007 .

[4]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[5]  E. Brandan,et al.  Betaglycan induces TGF-beta signaling in a ligand-independent manner, through activation of the p38 pathway. , 2006, Cellular signalling.

[6]  Brian Bierie,et al.  Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.

[7]  R. L. Baldwin,et al.  BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. , 2006, Gynecologic oncology.

[8]  E. Wallace,et al.  Activin A and inhibin A differentially regulate human uterine matrix metalloproteinases: potential interactions during decidualization and trophoblast invasion. , 2006, Endocrinology.

[9]  M. Björklund,et al.  Gelatinase-mediated migration and invasion of cancer cells. , 2005, Biochimica et biophysica acta.

[10]  Luzhe Sun,et al.  Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase‐9 expression in a human xenograft model of prostate cancer , 2005, The Prostate.

[11]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Bell,et al.  Origins and molecular pathology of ovarian cancer , 2005, Modern Pathology.

[13]  B. Vanderhyden,et al.  Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. , 2005, Molecular cancer research : MCR.

[14]  Colleen A Crane,et al.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  Robert Brown,et al.  The epigenetics of ovarian cancer drug resistance and resensitization. , 2004, American journal of obstetrics and gynecology.

[16]  H. Burger,et al.  Inhibin/activin and ovarian cancer. , 2004, Endocrine-related cancer.

[17]  Xiao-Fan Wang,et al.  ß-Arrestin 2 Mediates Endocytosis of Type III TGF-ß Receptor and Down-Regulation of Its Signaling , 2003, Science.

[18]  R. Weinberg,et al.  Heart and Liver Defects and Reduced Transforming Growth Factor β2 Sensitivity in Transforming Growth Factor β Type III Receptor-Deficient Embryos , 2003, Molecular and Cellular Biology.

[19]  S. Camper,et al.  Regulation of the Rat Follicle-Stimulating Hormone β-Subunit Promoter by Activin , 2003 .

[20]  T. Sato,et al.  Matrix metalloproteinases-2 and -9 activities in bovine follicular fluid of different-sized follicles: relationship to intra-follicular inhibin and steroid concentrations. , 2003, Domestic animal endocrinology.

[21]  H. Burger,et al.  Inhibin-activin receptor subunit gene expression in ovarian tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[22]  H. Lodish,et al.  A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. , 2001, The Journal of biological chemistry.

[23]  Harvey F. Lodish,et al.  Functional Roles for the Cytoplasmic Domain of the Type III Transforming Growth Factor β Receptor in Regulating Transforming Growth Factor β Signaling* , 2001, The Journal of Biological Chemistry.

[24]  R. Bast,et al.  Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. , 2001, Gynecologic oncology.

[25]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Takenoshita,et al.  Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers. , 2000, International journal of oncology.

[27]  K. Lewis,et al.  Betaglycan binds inhibin and can mediate functional antagonism of activin signalling , 2000, Nature.

[28]  N. Wake,et al.  Mutation analysis of the Smad3 gene in human ovarian cancers. , 1999, International journal of oncology.

[29]  R. L. Baldwin,et al.  Ovarian carcinoma cell cultures are resistant to TGF-beta1-mediated growth inhibition despite expression of functional receptors. , 1999, Gynecologic oncology.

[30]  Raymond B. Runyan,et al.  Requirement of type III TGF-beta receptor for endocardial cell transformation in the heart. , 1999, Science.

[31]  R. L. Baldwin,et al.  Altered expression of transforming growth factor‐β ligands and receptors in primary and recurrent ovarian carcinoma , 1999, Cancer.

[32]  Mohammed A. Khan,et al.  Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β , 1997, Oncogene.

[33]  W. Vale,et al.  Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation , 1997, Molecular and cellular biology.

[34]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[35]  J. Massagué,et al.  Activation of signalling by the activin receptor complex , 1996, Molecular and cellular biology.

[36]  M. Centrella,et al.  Expression of Transforming Growth Factor Type III Receptor in Vascular Endothelial Cells Increases Their Responsiveness to Transforming Growth Factor β2 (*) , 1995, The Journal of Biological Chemistry.

[37]  G. Stamp,et al.  Expression and activity of MMPS and their regulators in ovarian cancer , 1994, International journal of cancer.

[38]  J. Massagué,et al.  Type I receptors specify growth-inhibitory and transcriptional responses to transforming growth factor beta and activin , 1994, Molecular and cellular biology.

[39]  J. Massagué,et al.  Betaglycan presents ligand to the TGFβ signaling receptor , 1993, Cell.

[40]  A. Bradley,et al.  α-lnhibin is a tumour-suppressor gene with gonadal specificity in mice , 1992, Nature.

[41]  L. Liotta,et al.  Evaluation of Basement Membrane Components and the 72 kDa Type IV Collagenase in Serous Tumors of the Ovary , 1992, The American journal of surgical pathology.

[42]  L. Mathews,et al.  Cloning of a second type of activin receptor and functional characterization in Xenopus embryos. , 1992, Science.

[43]  A. Bradley,et al.  Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. , 1992, Nature.

[44]  L. Mathews,et al.  Expression cloning of an activin receptor, a predicted transmembrane serine kinase , 1991, Cell.

[45]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.